Literature DB >> 9021192

Effects of benzoxazinorifamycin KRM-1648 on cytokine production at sites of Mycobacterium avium complex infection induced in mice.

H Tomioka1, K Sato, T Shimizu, C Sano, T Akaki, H Saito, K Fujii, T Hidaka.   

Abstract

Although various antimicrobial agents exhibit appreciable microbicidal activity in the early phase (weeks 2 t0 4) of Mycobacterium avium complex (MAC) infection induced in mice, progressive bacterial regrowth subsequently occurs. To clarify the reason for this pattern of changes, we studied changes in the levels of various cytokines in tissue at sites of infection (spleens and lungs) of MAC-infected mice which were or were not given a benzoxazinorifamycin, KRM-1648 (KRM). Levels of the proinflammatory cytokines tumor necrosis factor alpha (TNF-alpha) and gamma interferon (IFN-gamma) in tissues temporarily increased at around weeks 2 to 4 after infection, rapidly decreased thereafter, and returned to normal by week 8. Similar but somewhat delayed changes were noted for levels of interleukin 10 (IL-10) and transforming growth factor beta (TGF-beta), immunosuppressive cytokines with macrophage (M phi)-deactivating activity, in tissue, except that TGF-beta levels in the spleen remained high during weeks 4 to 8. KRM treatment blocked the increase in the levels of all of those cytokines in tissue in the early phase of infection, most strongly at week 4. IL-6 levels were beneath the limit of detection throughout the observation period. Bacterial loads in the visceral organs decreased during the first 2 weeks, and KRM treatment markedly promoted this decrease. However, regrowth of MAC organisms began at weeks 2 to 4 and continued thereafter, even in KRM-treated mice. Splenocytes and splenic M phi s of MAC-infected mice (week 2) produced and/or released into the culture fluid significant amounts of TNF-alpha (in a cell-bound form), IFN-gamma, and IL-10, but not TGF-beta, during 3 days of cultivation. A substantial amount of TGF-beta was produced during 2 weeks of cultivation of peritoneal M phi s. KRM itself did not significantly affect the IL-10- and TGF-beta-producing ability of cultured M phi s. These findings suggest that IL-10 and TGF-beta play important roles in the regrowth of MAC organisms seen during the course of KRM treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9021192      PMCID: PMC163714     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  37 in total

1.  Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages.

Authors:  N Mor; B Simon; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

Review 2.  [Attempts to elucidate the reasons why mycobacterial infections are generally intractable].

Authors:  H Tomioka
Journal:  Nihon Saikingaku Zasshi       Date:  1995-07

Review 3.  Recombinant cytokines for controlling mycobacterial infections.

Authors:  L E Bermudez; G Kaplan
Journal:  Trends Microbiol       Date:  1995-01       Impact factor: 17.079

Review 4.  Disease due to the Mycobacterium avium complex in patients with AIDS: epidemiology and clinical syndrome.

Authors:  C A Benson
Journal:  Clin Infect Dis       Date:  1994-04       Impact factor: 9.079

5.  Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice.

Authors:  H Saito; H Tomioka; K Sato; S Kawahara; T Hidaka; S Dekio
Journal:  Tuber Lung Dis       Date:  1995-02

6.  Activity of KRM-1648 alone or in combination with both ethambutol and kanamycin or clarithromycin against Mycobacterium intracellulare infections in beige mice.

Authors:  T Yamamoto; R Amitani; K Suzuki; E Tanaka; T Murayama; F Kuze
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

7.  Production of TNF-alpha, IL-6 and TGF-beta, and expression of receptors for TNF-alpha and IL-6, during murine Mycobacterium avium infection.

Authors:  J Champsi; L S Young; L E Bermudez
Journal:  Immunology       Date:  1995-04       Impact factor: 7.397

8.  Role of gamma interferon and tumor necrosis factor alpha during T-cell-independent and -dependent phases of Mycobacterium avium infection.

Authors:  R Appelberg; A G Castro; J Pedrosa; R A Silva; I M Orme; P Minóprio
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

9.  Activation of mouse peritoneal macrophages in vitro and in vivo by interferon-gamma.

Authors:  H W Murray; G L Spitalny; C F Nathan
Journal:  J Immunol       Date:  1985-03       Impact factor: 5.422

10.  The role of tumor necrosis factor, interferon-gamma, transforming growth factor-beta, and nitric oxide in the expression of immunosuppressive functions of splenic macrophages induced by Mycobacterium avium complex infection.

Authors:  H Tomioka; K Sato; W W Maw; H Saito
Journal:  J Leukoc Biol       Date:  1995-12       Impact factor: 4.962

View more
  6 in total

1.  The modulating effects of proinflammatory cytokines interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha), and immunoregulating cytokines IL-10 and transforming growth factor-beta (TGF-beta), on anti-microbial activity of murine peritoneal macrophages against Mycobacterium avium-intracellulare complex.

Authors:  C Sano; K Sato; T Shimizu; H Kajitani; H Kawauchi; H Tomioka
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

2.  Effects of secretory leucocyte protease inhibitor on the production of the anti-inflammatory cytokines, IL-10 and transforming growth factor-beta (TGF-beta), by lipopolysaccharide-stimulated macrophages.

Authors:  C Sano; T Shimizu; K Sato; H Kawauchi; H Tomioka
Journal:  Clin Exp Immunol       Date:  2000-07       Impact factor: 4.330

3.  Roles of tumour necrosis factor-alpha (TNF-alpha), transforming growth factor-beta (TGF-beta), and IL-10 in the modulation of intercellular adhesion molecule-1 (ICAM-1) expression by macrophages during mycobacterial infection.

Authors:  H Tomioka; T Shimizu; W W Maw; K Ogasawara
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

4.  Effects of the Chinese traditional medicine mao-bushi-saishin-to on therapeutic efficacy of a new benzoxazinorifamycin, KRM-1648, against Mycobacterium avium infection in mice.

Authors:  T Shimizu; H Tomioka; K Sato; C Sano; T Akaki; S Dekio; Y Yamada; T Kamei; H Shibata; N Higashi
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

5.  Therapeutic effects of benzoxazinorifamycin KRM-1648 administered alone or in combination with a half-sized secretory leukocyte protease inhibitor or the nonsteroidal anti-inflammatory drug diclofenac sodium against Mycobacterium avium complex infection in mice.

Authors:  C Sano; T Shimizu; K Sato; H Kawauchi; S Kawahara; H Tomioka
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

6.  TGF-β-mediated sustained ERK1/2 activity promotes the inhibition of intracellular growth of Mycobacterium avium in epithelioid cells surrogates.

Authors:  Carolina L'Abbate; Ivone Cipriano; Elizabeth Cristina Pérez-Hurtado; Sylvia Cardoso Leão; Célia Regina Whitaker Carneiro; Joel Machado
Journal:  PLoS One       Date:  2011-06-22       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.